Journals / Journal of Surgery and Medicine / 2021 / Cilt: 5 - Sayı: 2

Experience of chronic thromboembolic pulmonary hypertension (CTEPH) in two cases with scleroderma and immunopathogenesis overview: Case report

Pages
188–192
Publication Date
2021-02-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to discuss the immunopathogenesis with two case reports.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic Sclerosis (SSc) is a multi-systemic connective tissue disease of unknown etiology.
📊
Key Findings & Data:Chronic thromboembolic hypertension (CTEPH) is in the group 4 PHT class.
💡
Conclusion & Impact:We aimed to discuss the immunopathogenesis with two case reports.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Scleroderma · Pulmonary Hypertension · CTEPH

Abstract

Systemic Sclerosis (SSc) is a multi-systemic connective tissue disease of unknown etiology. Although many pathological processes play a role in the basis of pulmonary hypertension (PHT) that develops secondary to SSc, vasculopathy has an important place. Chronic thromboembolic hypertension (CTEPH) is in the group 4 PHT class. CTEPH distinguishes it from other causes of PHT by having both surgical and medical treatment options. CTEPH is a pathology that develops chronically and can be overlooked due to its nonspecific symptoms. Early diagnosis and treatment can reduce morbidity and mortality. The physiopathology of vasculopathy secondary to CTEPH and vasculopathy of SSc made us suspect that similar processes operate in both diseases. The processes that cause and follow endothelial damage are similar in both diseases. If this pathophysiological mechanism can be clarified, possible new treatment options can be discovered. We diagnosed CTEPH with the examinations we performed in two of our patients with SSc and interstitial lung disease, both of which developed PHT. We aimed to discuss the immunopathogenesis with two case reports.

🔖

Cite This Article

OKYAR, B., ALBAYRAK, F., TORUN, B., ATİLLA, N., KIZILDAĞ, B., YILDIZ, F., ÇETİN, G. Y. (2021). Experience of chronic thromboembolic pulmonary hypertension (CTEPH) in two cases with scleroderma and immunopathogenesis overview: Case report. Journal of Surgery and Medicine, Cilt: 5 - Sayı: 2, 188–192. https://ajindex.com/articles/780086

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J. Systemic sclerosis. Nature Reviews Disease Primers. 2015
  2. 15002. doi:10.1038/nrdp.2015.2 2. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003
  3. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016
  4. 67–119. 4. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008
  5. 1122–7. 5. Mackel AM, DeLustro F, Harper FE, LeRoy EC. Antibodies to collagen in scleroderma. Arthritis Rheum. 1982
  6. Khaleh MB, LeRoy EC. Interleukin-2 in scleroderma:correlation of serum level with extent of skin involvement and dissease duration Ann Intern Med. 1989
  7. Silver RM. Lymphokine activated killer (LAK) cell activity in the peripheral blood of lymphosites of systemic sclerosis patients. Clin Exp Rhematology. 1990
  8. Rodnan GP, Myrewitz RL, Justh GO. Morphologicchanges in the digital arteries of patients with progresive systemic sclerosis and Raynaud phenomenon. Medicine. 1980
  9. Madge LA, Li JH, Choi J, Pober JS. Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003
  10. 278(23):21295-306. 10. Hussein MR, Hassan HI, Hofny ER, et al. Alterations of mononuclear inflamatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol. 2005
  11. 58(2):178-84. 11. Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003
  12. 120(4):596-606. 12. Krogsgaard M, Davis MM. How T cell'see'antigen. Nat Immunol.